CellSearch System cleared for monitoring metastatic breast cancer

Armen Hareyan's picture

Metastatic breast cancer monitoring

Veridex, a Johnson & Johnson company, today announced that the U.S. Food and Drug Administration (FDA) has granted an expanded clearance for the CellSearch

Share this content.

If you liked this article and think it may help your friends, consider sharing or tweeting it to your followers.